Aridis Pharmaceuticals Announces Asset Sale and Investment Proposal for Key Pipeline Candidates
• Aridis Pharmaceuticals has executed an agreement to sell AR-501, a therapeutic for chronic bacterial lung infections in cystic fibrosis, for $6.5 million plus royalties.
• The company is in discussions for an investment to fund the final Phase 3 study of AR-301, an adjunctive treatment for Ventilator Associated Pneumonia (VAP).
• A licensing dispute with MedImmune for AR-320, a VAP prevention candidate, remains unresolved, leading to the likely discontinuation of its Phase 3 trial.
© Copyright 2025. All Rights Reserved by MedPath